Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Mysimba

- PMLiVE

Gliptins don’t cause pancreatic cancer say FDA and EMA

Regulators back safety of diabetes medicine class

EU flag

Pharma wants review of EMA pharmacovigilance fees

EFPIA among associations to call for ‘balanced and transparent’ funding

- PMLiVE

Teva’s Symbicort generic backed for EU approval

AstraZeneca braces for competition to COPD drug

- PMLiVE

GSK’s Anoro backed in Europe for COPD

CHMP recommendation set to expand pharma company’s respiratory portfolio

- PMLiVE

EMA and FDA create pharmacovigilance ‘cluster’

Monthly meetings to discuss key issues in medicines safety

- PMLiVE

Senior changes at EMA

New head of IT and chair of committee for advanced therapies

- PMLiVE

EMA to expand orphan drug HTA collaboration

Will further develop the concept of parallel scientific advice in 2014

- PMLiVE

EU gives boost to its network of HTA bodies

EUnetHTA strengthens role in market access in EU

- PMLiVE

EMA brings transparency to its committee proceedings

Publishes meeting minutes of CHMP and two other advisory groups

- PMLiVE

CHMP turns down drugs for MS, cancer and muscular dystrophy

Negative EU recommendations for Teva, AB Science and PTC Therapeutics

Novartis building

CHMP denies Novartis’ heart failure drug

Panel refuses to recommend serelaxin for use in EU

- PMLiVE

GSK’s diabetes drug among CHMP recommendations

EMA committee also backs drugs from Bayer, Takeda and Linepharma France

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links